文献速递消化系统肿瘤

替莫唑胺联合伊立替康(TEMIRI方案)治疗MGMT甲基化、伊立替康敏感晚期结直肠癌的II期研究

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
PubMed 文献 · Ann Oncol · 2018-01-01

该II期 trial 评估TEMIRI方案在经治、伊立替康敏感、MGMT甲基化/MSS晚期结直肠癌患者中的疗效与安全性,主要终点ORR达到24%(95%CI 11%-43%),mPFS 4.4个月,mOS 13.8个月,≥3级不良事件仅16%,MGMT IHC阳性者均无缓解。

要点

  • TEMIRI在伊立替康敏感、MGMT甲基化MSS经治mCRC中ORR为24%,达到主要终点。
  • mPFS 4.4个月,mOS 13.8个月,≥3级不良事件发生率16%。
  • MGMT IHC阳性患者均无缓解,MGMT阴性/低表达者mPFS显著更长(6.9 vs 2.0个月)。

核心结论

  • TEMIRI方案在经治、伊立替康敏感且MGMT甲基化的mCRC患者中安全且有效。

研究设计与样本

  • II期 trial,入组25例经中心确认MGMT甲基化、MSS、至少二线化疗后进展且伊立替康无药间期>3个月的mCRC患者。
  • TEMIRI方案:替莫唑胺150 mg/m2 d1-5联合伊立替康100 mg/m2 d1、d15,每28天一次,共6周期,后续替莫唑胺维持。
  • 主要终点为总缓解率(ORR),探索性分析包括MGMT免疫组化(IHC)和甲基-BEAMing(MB)。

主要发现

  • 6例达部分缓解,ORR 24%(95%CI 11%-43%),达到主要终点。
  • 中位随访15.6个月,中位无进展生存期(mPFS)4.4个月,中位总生存期(mOS)13.8个月。
  • 仅4例(16%)出现≥3级不良事件(CTCAE 4.0)。
  • 所有MGMT IHC阳性患者均无缓解;MGMT阴性/低表达者mPFS显著更长(6.9 vs 2.0个月;HR=0.29,95%CI 0.02-0.41;P=0.003),mOS有延长趋势但未达统计学显著。
  • MB检测显示相似准确性。

关键数值与推荐

  • MGMT甲基化由中心实验室甲基化特异性PCR确认。
  • 入组要求MSS、至少二线化疗后进展、伊立替康无药间期>3个月。
  • TEMIRI剂量:替莫唑胺150 mg/m2 d1-5,伊立替康100 mg/m2 d1、d15,q28d。

临床怎么用

  • 对于经治、伊立替康敏感且MGMT甲基化的MSS mCRC患者,TEMIRI可作为 salvage 治疗选择。
  • MGMT IHC阳性可能提示TEMIRI疗效不佳,MGMT阴性/低表达者可能更获益。

局限性

  • 样本量小(25例),为单臂II期 trial,结论需更大样本验证。
  • MGMT IHC与MB的预测价值为探索性分析,尚未确立为标准生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-randomized studies showed that temozolomide (TMZ) achieves an average 10% response rate in heavily pretreated metastatic colorectal cancer (mCRC) patients with promoter methylation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT). In this phase II trial, irinotecan and temozolomide (TEMIRI) combination regimen was assessed in irinotecan-sensitive, MGMT methylated/microsatellite stable (MSS) pretreated mCRC patients. PATIENTS AND METHODS: Key inclusion criteria were centrally confirmed MGMT methylation by methylation-specific PCR, MSS mCRC, progression after at least two prior chemotherapy regimens for advanced disease and irinotecan-free interval >3 months. TEMIRI (TMZ 150 mg/m2 on days 1-5 plus irinotecan 100 mg/m2 on days 1, 15 q28 days) was administered for six cycles, followed by maintenance with TMZ. The primary end point was overall response rate (ORR). Exploratory translational analyses included MGMT immunohistochemistry (IHC) and methyl-BEAMing (MB). RESULTS: Between December 2014 and June 2017, 25 patients were enrolled. The primary end point was met, since six patients achieved a partial response [ORR 24%, 95% confidence interval (CI) 11% to 43%]. At a median follow-up of 15.6 months, median progression-free survival (mPFS) and overall survival (mOS) were 4.4 and 13.8 months, respectively. Only four (16%) patients had ≥ grade 3 (CTCAE 4.0) adverse events. All patients whose cancer was MGMT-positive IHC were non-responders. Consistently, patients with MGMT-negative/low tumors had a significantly longer mPFS than others (6.9 versus 2.0 months; hazard ratio = 0.29, 95% CI 0.02-0.41; P = 0.003) and a non-significant trend for longer mOS. MB testing showed similar accuracy. CONCLUSIONS: TEMIRI regimen is a safe and active option in pre-treated, irinotecan-sensitive mCRC patients with MGMT methylation.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Morano F, Corallo S, Niger M, et al. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Ann Oncol. 2018. PMID: 29860358. doi:10.1093/annonc/mdy197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。